BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38369463)

  • 1. C-Myc protein expression indicates unfavorable clinical outcome in surgically resected small cell lung cancer.
    Lang C; Megyesfalvi Z; Lantos A; Oberndorfer F; Hoda MA; Solta A; Ferencz B; Fillinger J; Solyom-Tisza A; Querner AS; Egger F; Boettiger K; Klikovits T; Timelthaler G; Renyi-Vamos F; Aigner C; Hoetzenecker K; Laszlo V; Schelch K; Dome B
    World J Surg Oncol; 2024 Feb; 22(1):57. PubMed ID: 38369463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small-cell lung cancer: an international multicenter study.
    Megyesfalvi Z; Barany N; Lantos A; Valko Z; Pipek O; Lang C; Schwendenwein A; Oberndorfer F; Paku S; Ferencz B; Dezso K; Fillinger J; Lohinai Z; Moldvay J; Galffy G; Szeitz B; Rezeli M; Rivard C; Hirsch FR; Brcic L; Popper H; Kern I; Kovacevic M; Skarda J; Mittak M; Marko-Varga G; Bogos K; Renyi-Vamos F; Hoda MA; Klikovits T; Hoetzenecker K; Schelch K; Laszlo V; Dome B
    J Pathol; 2022 Aug; 257(5):674-686. PubMed ID: 35489038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular subtypes, predictive markers and prognosis in small-cell lung carcinoma.
    Zhu Y; Li S; Wang H; Ren W; Chi K; Wu J; Mao L; Huang X; Zhuo M; Lin D
    J Clin Pathol; 2023 Sep; ():. PubMed ID: 37775262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MYCL1 Amplification and Expression of L-Myc and c-Myc in Surgically Resected Small-Cell Lung Carcinoma.
    Qin J; Xie F; Li C; Han N; Lu H
    Pathol Oncol Res; 2021; 27():1609775. PubMed ID: 34257619
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical characteristics and patient outcomes of molecular subtypes of small cell lung cancer (SCLC).
    Ding XL; Su YG; Yu L; Bai ZL; Bai XH; Chen XZ; Yang X; Zhao R; He JX; Wang YY
    World J Surg Oncol; 2022 Feb; 20(1):54. PubMed ID: 35220975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and prognostic implications of CD47 and PD-L1 expression in surgically resected small-cell lung cancer.
    Lang C; Lantos A; Megyesfalvi Z; Egger F; Hoda MA; Mosleh B; Klikovits T; Oberndorfer F; Timelthaler G; Ferencz B; Fillinger J; Schwendenwein A; Querner AS; Boettiger K; Renyi-Vamos F; Hoetzenecker K; Laszlo V; Schelch K; Dome B
    ESMO Open; 2022 Dec; 7(6):100631. PubMed ID: 36399951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Implications of Molecular Subtypes in Primary Small Cell Lung Cancer and Their Correlation With Cancer Immunity.
    Qi J; Zhang J; Liu N; Zhao L; Xu B
    Front Oncol; 2022; 12():779276. PubMed ID: 35311069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular subtype expression and genomic profiling differ between surgically resected pure and combined small cell lung carcinoma.
    Zhu Y; Li S; Wang H; Chi K; Ren W; Huang X; Zhuo M; Lin D
    Hum Pathol; 2023 Nov; 141():118-129. PubMed ID: 37586462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of ASCL1, NEUROD1, and POU2F3 expression in surgically resected specimens, paired tissue microarrays, and lymph node metastases in small cell lung carcinoma.
    Handa T; Hayashi T; Ura A; Watanabe I; Takamochi K; Onagi H; Kishi M; Matsumoto N; Tajima K; Kishikawa S; Saito T; Takahashi K; Suzuki K; Yao T
    Histopathology; 2023 May; 82(6):860-869. PubMed ID: 36715573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Subtypes of Primary SCLC Tumors and Their Associations With Neuroendocrine and Therapeutic Markers.
    Qu S; Fetsch P; Thomas A; Pommier Y; Schrump DS; Miettinen MM; Chen H
    J Thorac Oncol; 2022 Jan; 17(1):141-153. PubMed ID: 34534680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole-Section Landscape Analysis of Molecular Subtypes in Curatively Resected Small Cell Lung Cancer: Clinicopathologic Features and Prognostic Significance.
    Hwang S; Hong TH; Kim HK; Choi YS; Zo JI; Shim YM; Han J; Chan Ahn Y; Pyo H; Noh JM; Lee HY; Kim HJ; Park S; Ahn MJ; Park K; Lee SH; Choi YL; Kim J
    Mod Pathol; 2023 Jul; 36(7):100184. PubMed ID: 37054974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization.
    Baine MK; Hsieh MS; Lai WV; Egger JV; Jungbluth AA; Daneshbod Y; Beras A; Spencer R; Lopardo J; Bodd F; Montecalvo J; Sauter JL; Chang JC; Buonocore DJ; Travis WD; Sen T; Poirier JT; Rudin CM; Rekhtman N
    J Thorac Oncol; 2020 Dec; 15(12):1823-1835. PubMed ID: 33011388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate.
    Ireland AS; Micinski AM; Kastner DW; Guo B; Wait SJ; Spainhower KB; Conley CC; Chen OS; Guthrie MR; Soltero D; Qiao Y; Huang X; Tarapcsák S; Devarakonda S; Chalishazar MD; Gertz J; Moser JC; Marth G; Puri S; Witt BL; Spike BT; Oliver TG
    Cancer Cell; 2020 Jul; 38(1):60-78.e12. PubMed ID: 32473656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical utility of immunohistochemical subtyping in patients with small cell lung cancer.
    Chiang CL; Huang HC; Luo YH; Shen CI; Chao HS; Tseng YH; Chou TY; Schrump DS; Yeh YC; Chen YM
    Lung Cancer; 2024 Feb; 188():107473. PubMed ID: 38232600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High mRNA expression of POU2F3 in small cell lung cancer cell lines predicts the effect of lurbinectedin.
    Matsui S; Haruki T; Oshima Y; Kidokoro Y; Sakabe T; Umekita Y; Nakamura H
    Thorac Cancer; 2022 Apr; 13(8):1184-1192. PubMed ID: 35278040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological features and prognostic implications of ASCL1 expression in surgically resected small cell lung cancer.
    Wei J; Liu L; Guo Y; Zhang J; Wang X; Dong J; Xing P; Ying J; Yang L; Li J
    Thorac Cancer; 2021 Jan; 12(1):40-47. PubMed ID: 33191657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. YAP1 protein expression has variant prognostic significance in small cell lung cancer (SCLC) stratified by histological subtypes.
    Wang X; Guo Y; Liu L; Wei J; Zhang J; Xie T; Dong J; Li J; Xing P; Yang L
    Lung Cancer; 2021 Oct; 160():166-174. PubMed ID: 34364705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein Expression of immune checkpoints STING and MHCII in small cell lung cancer.
    Dora D; Rivard C; Yu H; Pickard SL; Laszlo V; Harko T; Megyesfalvi Z; Gerdan C; Dinya E; Hoetzenecker K; Hirsch FR; Lohinai Z; Dome B
    Cancer Immunol Immunother; 2023 Mar; 72(3):561-578. PubMed ID: 35978199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702).
    Furuta M; Sakakibara-Konishi J; Kikuchi H; Yokouchi H; Nishihara H; Minemura H; Harada M; Yamazaki S; Akie K; Fujita Y; Takamura K; Kojima T; Harada T; Minami Y; Watanabe N; Oizumi S; Suzuki H; Nishimura M; Dosaka-Akita H; Isobe H;
    Oncologist; 2019 Nov; 24(11):e1172-e1179. PubMed ID: 31068386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of Small Cell Lung Cancer Molecular Subtyping Markers to Small Cell Neuroendocrine Carcinoma of the Cervix: NEUROD1 as a Poor Prognostic Factor.
    Kim G; Kim M; Nam EJ; Lee JY; Park E
    Am J Surg Pathol; 2024 Mar; 48(3):364-372. PubMed ID: 37981832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.